15 studies found for:    omalizumab, urticaria
Show Display Options
Rank Status Study
1 Completed
Has Results
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Condition: Chronic Urticaria
Interventions: Drug: Omalizumab 75-375 mg;   Drug: Placebo to omalizumab;   Drug: Loratadine;   Drug: Clemastine
2 Completed Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
Conditions: Chronic Urticaria;   Chronic Idiopathic Urticaria;   Chronic Spontaneous Urticaria
Interventions: Drug: Omalizumab (Xolair);   Drug: Placebo
3 Completed
Has Results
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo
4 Completed
Has Results
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: Placebo;   Drug: Omalizumab
5 Completed
Has Results
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: omalizumab;   Drug: placebo;   Drug: H1 antihistamines;   Drug: Diphenhydramine
6 Active, not recruiting Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria
Condition: Chronic Urticaria
Interventions: Biological: Omalizumab;   Biological: Placebo
7 Completed
Has Results
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo;   Drug: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist;   Drug: Diphenhydramine
8 Completed Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: IGE025;   Drug: placebo
9 Recruiting Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
Condition: Chronic Urticaria
Intervention: Drug: Omalizumab
10 Recruiting Cold Urticaria Treatment With Xolair
Condition: Cold Contact Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo
11 Recruiting Efficacy Study of Omalizumab in Cholinergic Urticaria
Condition: Cholinergic Urticaria
Interventions: Biological: Active;   Biological: Placebo;   Biological: Open labeled
12 Active, not recruiting Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
Conditions: Chronic Spontaneous Urticaria;   Angioedema
Interventions: Biological: Omalizumab;   Drug: Placebo
13 Completed Effect of Anti-IgE in Chronic Urticaria
Condition: Urticaria
Intervention: Drug: Xolair® (Omalizumab)
14 Recruiting The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
Condition: Mastocytosis
Intervention: Drug: injections
15 Recruiting A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
Conditions: Anaphylaxis;   Hypotension;   Bronchospasm;   Angioedema
Interventions: Drug: Epinephrine;   Procedure: Bone Marrow Apsiration;   Drug: Omalizumab (Xolair)

Indicates status has not been verified in more than two years